Figure 7.

Enzyme-activatable nanomedicine for cancer theranostics. A) MMP2-induced disassembly of a nanozyme for PAI, MRI, and photothermal ferroptosis therapy. a) Schematic of the fabrication of the nanozyme and its disassembly in response to MMP2. b) T2-weighted MR images and corresponding plots of the nanozyme incubated with or without MMP2. c) Western blots analysis of ferroptosis- and apoptosis-related protein expression in 4T1 cells after different treatments. Reproduced with permission ¹⁵³. Copyright 2022, Wiley-VCH. B) Cathepsin B-induced degradation of gadolinium-labeled branched glycopolymer-PTX conjugates for MRI, fluorescence imaging, and chemotherapy. a) Schematic design. b) Size-exclusion chromatography profiles for this conjugate before and after incubation with cathepsin B. c) Distribution of this conjugate in major organs determined by the gadolinium retention. d) Tumor growth curves after different treatments. Reproduced with permission ¹⁵⁴. Copyright 2021 the Authors, published by Elsevier B.V. C) Myeloperoxidase-induced aggregation of HZ-5 NPs for neutrophil-targeting PDT or PET. a) Schematic of the aggregation process of HZ-5 NPs. b) PET images of 4T1 tumors after i.v. injection of ⁶⁴Cu-labeled HZ-5 NPs. e) The counts of lung metastatic noduli in the mice treated with different methods. Reproduced with permission ¹⁵⁵. Copyright 2020, Wiley-VCH.